Reference | Drug | RA duration | Activity at discontinuation | Number discontinued/ continued | Follow-up (weeks) | DAS28 < 3.2 at end (%) | DAS28 < 2.6 at end (%) | SDAI ≤ 3.3 at end (%) | |||
---|---|---|---|---|---|---|---|---|---|---|---|
 |  |  |  |  |  | Discontinued | Continued | Discontinued | Continued | Discontinued | Continued |
Double-blind controlled trials | |||||||||||
 Smolen OPTIMA 2014 [22] | ADA | Early | DAS28-CRP < 3.2 at weeks 22 and 26 | 102/105 | 52 | 81.2 | 91.4 | 66.3 | 85.7 | 50.5 | 61.9 |
 Emery 2014 [23] | ETA | Early | DAS28-ESR < 3.2 at week 39 and DAS28-ESR < 2.6 at week 52 | 65/63 | 39 | 69.2 | 88.8 | 53.8 | 79.3 | - | - |
 Smolen PRESERVE 2013 [24] | ETA | Est | DAS28-ESR < 3.2 over 24 weeks | 200/202 | 52 | 42.6 | 82.6 | 29.4 | 66.7 | 11.7 | 37.8 |
 Pavelka 2017 [25] | ETA | Est | DAS28-ESR < 3.2 at week 24 | 176/167 | 28 | 17 | 44 | 13 | 34 | 13 | 25 |
 Weinblatt 2017 [26] | CTZ | Early | DAS28-ESR < 3.2 for 12 weeks | 82/84 | 52 | 39.2 | 48.8 | 33.3 | 44.0 | - | - |
Open-label trials | |||||||||||
 Yamanaka 2016 [27] | ETA | Early | DAS28 < 2.6 for 6 months | 34/33 | 52 | - | - | 53.6 | 87.5 | 46.4 | 81.3 |
Observational studies | |||||||||||
 Quinn 2005 [28] | INF | Early | DAS28 < 2.6 | 6/- | 50 | - | - | 83 | - | - | - |
 Van der Bijl 2007 [29] | INF | Early | DAS ≤ 2.4 for 6 months | 77/- | 66 | - | - | 87.0 | - | - | - |
 Nawata 2008 [30] | INF | Early | DAS28-ESR < 2.6 for ≥ 6 months | 9/- | 24 | - | - | 100 | - | - | - |
 Soubrier 2009 [31] | ADA | Early | DAS28 < 3.2 after 12 weeks of treatment | 33/ | 40 | 33.3 | - | - | - | - | - |
 Lagana 2009 [32] | ETA | Early | DAS < 1.6 after 12 months | 8/- | 52 | - | - | 100 | - | - | - |
 Saleem 2010 [33] | ADA 74% INF 26% | Early | DAS28 < 2.6 for ≥ 6 months | 27/- | 96 | - | - | 59.2 | - | - | - |
 Migliore 2010 [34] | ETA 43% ADA 28% INF 28% | Early | DAS28 < 3.2 | 21/- | 24 | 61.9 | - | - | - | - | - |
 Migliore 2011 [35] | ETA 46% ADA 26% INF 28% | Early | DAS28 < 3.2 | 50/- | 52 | 42.0 | - | - | - | - | - |
 Harigai 2012 [36] | ADA | Est | DAS28-CRP < 2.7 | 22/24 | 52 | - | - | 18.1 | 66.6 | - | - |
 Nam IDEA 2014 [37] | INF | Early | DAS < 1.6 for 6 months | 14/- | 28 | - | - | 78.6 | - | - | - |
 Nam EMPIRE 2014 [38] | ETA | Early | No tender or swollen joints for > 26 weeks | 2/- | 26 | - | - | 100 | - | - | - |
 Tanaka HONOR 2015 [39] | ADA | Est | DAS28-ESR < 2.6 for ≥ 6 months | 52/23 | 52 | 62 | 91 | 48 | 83 | 60 | 70 |
 Smolen 2015 [40] | CTZ | Est | CDAI ≤ 2.8 for 5 weeks | 17/6 | 28 | - | - | - | - | 17.6b | 33.3b |
 Tanaka HOPEFUL-2 2016 [41] | ADA | Early | DAS28-ESR < 3.2 for ≥ 6 weeks | 80/73 | 52 | 80.0 | 97.2 | - | - | - | - |
 Inui 2018 [42] | ETA | Est | DAS28-ESR < 3.2 at one visit | 18/- | 96 | 27.7 | - | - | - | - | - |
 Tanaka RRRR 2020 [43] | INF | Est | SDAI ≤ 3.3 | 119/- | 52 | 63.8a | - | - | - | - | - |